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Fast typing methods for third generation cephalosporin resistance mechanisms 
are needed to guide appropriate treatment and prevent potential dissemination events. In 
this study we used a novel short and fast methodology for the identification of CMY-2  
in 50 well characterized clinical isolates of E. coli by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry- MALDI-TOF MS. Samples  
were prepared using the double layer sinapinic acid technique for detection of intact 
proteins Comparison among mass spectral profile of different strains between m/z 
35,000 – 45,000 Da showed that two groups of isolates could be differentiated after 
peak analysis. A single distinctive peak with different intensities, at approximately m/z 
39,800 Da was found in all CMY-2 producing strains (transconjugant, transformant and 
wild type) and consistently absent in the control groups (ESBL producers and 
susceptible strains). Statistical results showed 100 % values for sensitivity and 
specificity, indicating a perfect test and a high discriminative power. In this study, we 
demonstrated that MALDI-TOF MS has the potential to detect directly the most 
clinically relevant acquired AmpC β-lactamase, the CMY-2-enzyme, in E. coli with a 
less time-consuming process as compared to conventional methods. Our results may 
constitute the basis for further research to detect other β-lactamases, or even other 
resistance markers. 
 


















Resistance to third generation cephalosporins (TGC) is one of the most relevant 
problems in current Gram–negative antimicrobial therapy, leading to overuse of 
carbapenems and emergence of different carbapenemases. Outstanding from others, 
different plasmid borne extended spectrum β-lactamases (ESBL) families and plasmid-
determined AmpC-type β-lactamases are the most relevant resistance mechanisms. 
Among them, CTX-M-type and CMY-2 β-lactamases are the most frequent resistance 
markers worldwide, respectively (Gutkind et al., 2013). 
Phenotypic methods, as double disk synergy tests using β-lactam and β-
lactamase-inhibitor disks, and even the original double disk approximation tests remain 
convenient, easy to perform, but not fast methods for detecting these β-lactamase in 
Gram-negative bacilli. 
Clinical microbiology laboratories are expected nowadays to provide a proper 
characterization of the involved mechanisms for an effective antimicrobial therapy 
(Morency-potvin et al., 2017). Fast typing methods for third generation cephalosporin 
(TGC) resistance mechanisms are necessary to guide an appropriate antimicrobial 
treatment scheme and prevent potential dissemination events (Rhodes et al., 2017). This 
is also the case for any resistance mechanism, and different genotypic systems have 
been developed for achieving this goal. 
Incorporation of matrix-assisted laser desorption ionization–time of flight mass 
spectrometry (MALDI-TOF MS) has been one of the most significant breakthrough 
technologies that re defined modern clinical microbiology, and is today routinely used 
in high complexity laboratories for rapid species identification (Sandalakis et al., 2017). 
















predict β-lactamase production based on the detection of hydrolyzed β-lactam 
substrates. This hydrolysis is evaluated after at least one hour of incubation in the 
presence of the bacteria (Hooff et al., 2012; Oviaño et al., 2016; Sparbier et al., 2012). 
Following this methodology, enzyme detection is feasible but only reflects the presence 
of at least one enzyme with hydrolytic activity on the provided substrate. 
Direct detection of a specific enzyme by analysis of the MALDI-TOF MS 
generated protein profile has been the subject of research in different studies. Among 
them, Camaro and Hays were the first to detect a peak corresponding to the β-lactamase 
TEM-1, analyzing the spectrum of proteins in  bacterial lysates of E. coli susceptible 
and resistant to ampicillin (Camara and Hays, 2007). More recently, Papagiannitsis et al 
detected CMY-2 enzyme in different enterobacteria after extraction of periplasmic 
proteins using a multiple steps procedure (Hart et al., 2015; Papagiannitsis et al., 2014).  
Antibiotic resistance has been predicted by MALDI-TOF in the identification 
mass range by detection of biomarkers associated with a specific resistance determinant. 
In this respect, the hypothetical protein named p019 (11.109 Da) linked to the 
transposon Tn4401a was used to predict KPC carbapenemase producers (Gaibani et al., 
2016; Youn et al., 2016). In Staphylococcus aureus the peptide PSM-mec (2.413 Da) 
was associated with the methicillin resistance (Rhoads et al., 2016). Detection of these 
markers is relevant if only very conserved platforms are associated to the resitance 
marker. On the other hand, direct intact β-lactamase detection can be directly associated 
to protein expression, inferring the resistance patterns of bacteria. 
In the present study, we describe an easy and quick methodology for the 
identification of mature CMY-2 β-lactamase by MALDI-TOF in clinical isolates of 
















method is based on total protein extraction analysis using an organic solvent, and further 
detection of the mature protein given its theoretical molecular weight (This material was 
partially presented at ASM Microbe 2017, New Orleans). 
2 Materials and Methods 
2.1 Bacterial strains and β-lactamases characterization 
Sixty three previously characterized Enterobacterales clinical strains (50 E. coli, 4 
Klebsiella pneumoniae, 3 Proteus mirabilis and 6 Salmonella spp.), deposited at our 
laboratory collection in Buenos Aires, Argentina, were included (Table 1). Even if the 
initial attempts were done on bona fide transconjugant, transformant and recipient 
strains, finally 29 unrelated CMY-2 producing clinical isolates of E. coli and 21different 
blaCMY-2 negative E. coli isolates were incorporated. There was no epidemiological link 
among these isolates. Other species of CMY-2-producing Enterobacterales were also 
tested (Table 1). E. coli ATCC 25922 and E. coli ATCC 35218 were also included as 
negative controls. All isolates were previously characterized both phenotypically (by 
disk diffusion method and synergy test) and genotypically (by PCR and sequencing) 
aimed at different β-lactamase gene families (CMY-, TEM-, CTX-M-). Assays were 
performed as already described (Cejas et al., 2012; Rincón Cruz et al., 2013; Saba 
Villarroel et al., 2017). As test material, cultures were obtained on Mueller Hilton (MH) 
(Britania, Argentina) agar plates without antibiotics (for all susceptible and resistant 
isolates) or in MH agar plates supplemented with ampicillin (Sigma-Aldrich, USA) 100 
mg/L (for all resistant isolates), incubated overnight at 37°C.  
2.2 Sample preparation for MALDI-TOF MS 
The organic solvent extraction method was fine-turned in this work in order to 
















Matsuda et al (Matsuda et al., 2012). Briefly, a loopful of  bacterial colonies (4-5 
colonies) was suspended in 300 μl distilled water and mixed by vortexing for 30 s. After 
that 900 µl of room temperature absolute ethanol (Sigma-Aldrich, USA) were added. 
The suspension was vortexed vigorously for 30 s and centrifuged at 17,000 x g for 2 
min at room temperature. After discarding the supernatant, the pellet was re-suspended 
in 100 µl of extraction solvent (formic acid - isopropyl alcohol - water, 17:33:50 ratio 
by volume) (Sigma-Aldrich, USA), vortexed for 30 s, and then centrifuged at 17,000 x g 
for  2 min at room temperature to obtain the clean supernatant extract.  
2.3 Target spot loading  
The double layer sinapinic acid (SA) (Bruker Daltonics, Germany) technique was 
used for intact protein detection. To form the first layer, 0.7 µl of a saturated solution of 
SA in absolute ethanol was loaded onto a MALDI target spot and dried at room 
temperature. As a second layer, the protein extracts were mixed 1:1 with SA 10 g/L 
solution (30:70 [v/v] acetonitrile: 0.1% trifluoroacetic acid in water) (Sigma-Aldrich, 
USA). One µL of the sample/matrix mixture was then deposited onto the first layer. 
Samples were dried at room temperature before being placed in the mass spectrometer 
(Keller and Li, 2006). Each sample was analyzed by triplicate, loaded three times on 
different spots of the stainless steel MALDI target plate. 
2.4 Spectra acquisition and statistical analysis 
The mass spectra were obtained using a Microflex LT mass spectrometer by 
flexControl3.4 software (Bruker Daltonics, Germany). The parameters were set up as 
follows: linear positive ion mode within the mass range of 17,000 Da to 50,000 Da. 
Spectrometer ion source 1, 19.98 kV; ion source 2, 17.93 kV; lens 5.50 kV; pulsed ion 
extraction 260 ns; detection gain, 2877 V; sample rate and electronic setting 0.50 GS/s; 
















Spectra of each spot were captured twice in automatic mode. Each spectrum was 
obtained after 800 shots (16×50 laser shots for random walk in partial sample) per spot. 
Data were automatically acquired using AutoXecute acquisition control software 
(Bruker Daltonics, Germany). Spectra were analyzed using flexAnalysis 3.4 software 
(Bruker Daltonics). Before each run, Microflex LT mass spectrometer was externally 
calibrated using the Standard II calibration mixture (Bruker Daltonics). 
All spectra were assessed with the software ClinProTools 3.0 (Bruker Daltonics, 
Germany) (Ketterlinus et al., 2005).  
2.5 Mass spectrometry analysis 
In order to confirm the presence of the CMY-2 β-lactamase, the total protein 
extraction corresponding to CMY-2 producing E. coli 9238-3013 and the non-CMY-2 
producing E. coli T1 strains were initially dried under vacuum (speed-vac) 70 min to 
evaporate the organic solvent. Next, a volume containing 20 μg of protein was subjected 
to disulfide bond reduction with 20 mM dithiothreitol for 45 min at 56 °C, and 
alkylation with 20 mM iodoacetamide for 45 min at room temperature in the dark. Both 
samples were dissolved in 50 mM NH4HCO3 buffer, pH 8. Finally, trypsin proteolytic 
digestion was performed overnight. The samples were analyzed by nanoHPLC (EASY-
Spray Accucore, Thermo scientific, West Palm Beach, FL, USA) coupled to a mass 
spectrometer with Orbitrap technology (Q-Exactive, Thermo Scientific, West Palm 
Beach, FL, USA), enabling both separation and identification of peptides. Ionization of 
samples was made by electrospray (EASY-SPRAY, Thermo Scientific, West Palm 
Beach, FL, USA) and data analysis was performed by the Proteome Discoverer software 
version 1.4, Thermo Scientific. Coverage percentages were calculated based on the 

















2.6 Direct detection of CMY-2 from blood culture broths using MALDI-TOF MS 
An experimentally test was carried out on blood cultures in order to evaluate the 
present methodology directly on these samples. Three blood culture bottles (BACTEC® 
Plus Aerobic bottles) were inoculated with 2 ml of human blood mixed with different 
bacterial suspensions (approximately 10
4
 CFU/ml): E. coli 9238-3013 and E. coli 47688 
(both CMY-2 producers) and E. coli T1 (CTX-M-15 producer, as negative control). 
Blood cultures were incubated at 37 °C for 18 h. To remove blood cells, 1.4 ml of the 
positive cultures were centrifuged at 200 x g for 5 min. The supernatant was then 
centrifuged at 14,170 x g for 1 min at room temperature (Rodríguez-Sánchez et al., 
2014). Further, each pellet was subjected to the same protein extraction methodology 
described above. All samples were tested in duplicate. 
 
3 Result and discussion 
Initial experiments were focused on obtaining characteristic MALDI-TOF-MS 
spectra, especially in the range between m/z 35,000 – 45,000 Da. Thus, CMY-2 
producing E. coli HBC1a1 (transconjugant) and E. coli HB101 (recipient) were 
processed, and a characteristic peak around 39,800 Da (slightly differing from the 
expected value for the mature CMY-2 enzyme, 39,854 Da) was observed only in the 
transconjugant strain (Figure 1a). In addition, E. coli DH5α harboring the recombinant 
plasmid pBC-SK- CMY-2 (called pBL-II-CMY-2) showed this specific peak when was 
compared with the isogenic strain (E. coli DH5αpBC-SK) (Figure 1b). These CMY-2-
producing strains were used as positive control when the different wild-type isolates 
















Subsequently, all clinical enterobacterial isolates (n = 63) included in the study were 
processed under the same conditions by MALDI-TOF MS. Comparison among mass 
spectral profile of different E. coli clinical strains showed that two groups of isolates 
could be differentiated after peak analysis in the m/z range above mentioned. A single 
distinctive peak with different intensities, at approximately m/z 39,800 Da was found in 
all CMY-2 producing E. coli strains) and consistently absent in the CMY-2 negative 
strains included (Figure 1c). The presence of this distinctive peak was also dobserved in 
CMY-2 producing isolates of other Enterobacterales members (Table 1 and Figure 2). 
Analysis of replicate cultures of all isolates gave simple and consistent mass spectral 
profiles within this range.  
Statistical analysis was performed using the full raw spectra (17,000 to 50,000 
Da) and the “Peak Statistic Calculation” (ClinProTools) which included the 39,800 Da-
peak corresponding to mature CMY-2 protein. Statistical results showed a p-value < 
0.000001 (by both PAD and PWKW tests) which confirmed a significant difference for 
the selected peak (Stephens, 1974). Consistently, the area under the curve (AUC) of the 
ROC curve for this specific peak was 1.0 (100 % values for sensitivity and specificity), 
indicating a perfect test and a high discriminative power. 
In order to assess if the CMY-2 peak was altered in E. coli depending on 
ampicillin induction, about one half (17/29) CMY-2 producers were compared after 
growth in medium with or without ampicillin (100 mg/L). Results did not show any 
difference in intensity or position (m/z) of this distinctive peak (39,800 Da) in the 

















 The presence of CMY-2 in E. coli 9238-3013, positive in the MALDI-TOF MS 
assay, was reliably confirmed by protein identification by NanoHPLC coupled to a mass 
spectrometer with Orbitrap technology which revealed two CMY-2 compatible peptides 
(Table 2). Consistently, these two peptides were not detected in the non-CMY-2 
producing culture (E. coli T1). 
Finally, the CMY-2 β-lactamase could be directly detected from blood culture 
bottles.. In good agreement with our previous results, the distinctive peak of 
approximately 39,800 Da, corresponding to CMY-2, was observed in both spectra of 
CMY-2-producing E. coli, but not in the CTX-M-15 producer. 
In this study, we demonstrated that MALDI-TOF MS has the potential to detect, 
in a quick, easy and inexpensive procedure,  the most clinically relevant acquired AmpC 
β-lactamase, the CMY-2-enzyme, both on E. coli plates, and even in other 
Enterobacterales, however the incidence of this enzyme in other species than E. coli is 
negligible. Even if still preliminary, this approach may be useful directly on positive 
blood cultures bottles. 
Once the technology is in place, MALDI-TOF MS applications are fast and low-
cost techniques. MALDI-TOF MS approaches are faster than any phenotypic or 
genotypic procedure currently used in the clinical laboratory for resistance marker 
detection, as disk diffusion method and PCR plus sequencing. Compared with previous 
MALDI-TOF MS procedures developed for detection of CMY-2 producing E. coli 
(Papagiannitsis et al., 2014), the present one employs a single solvent extraction (formic 
acid - isopropyl alcohol - water) step without any incubation period consuming less than 
1-h turnaround time. Moreover, this can be run while processing samples for microbial 
















mandatory end point time. Furthermore, the time required is substantially lower than 
that needed for hydrolysis products detection as well as less labour-consuming (Mirande 
et al., 2015; Papagiannitsis et al., 2014). The procedure presented in this study, does not 
require additional reagents to those available and used routinely for microorganism 
identification by MALDI-TOF MS, except for isopropyl alcohol and sinapinic acid. 
This simple approach requires an additional acquisition method optimized for 
the mass range from 17,000 – 50,000 Da and also, an extra independent sample 
preparation is necessary to assess the resistance marker detection. Nevertheless, this 
improvement is an important step towards routine application.  
Our results may constitute the basis for further research to detect in a rapid and 
reliable way other proteins, under similar conditions. Overall, if the method can be 
extended to other β-lactamases, or even other resistance markers, may prove a 
significant improvement in laboratory abilities for their detection with extensive clinical 
implications, and we strongly believe that appropriate validations will definitely lead to 
establishing a MALDI-TOF supplementary database for future applications in 
diagnostic laboratories and reference centers. 
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Figure 1.Peaks of MALDI-TOF MS of the CMY-2 and non-CMY-2 producing E. coli 
using a mass range from 35,000 to 45,000 Da. (a) Peak detection of ~39,800 Da in the 
E. coli transconjugant strain (HBC1a1) is indicated with arrow on the red line plot; 
absence of the 39,800-m/z peak in the recipient strain (HB101) is observed on the green 
line plot. (b) Peak detection of ~39,800 Da in the E. coli harboring the recombinant 
plasmid with CMY-2 (E. coliDH5α/pBC-SK-CMY-2) is indicated with arrow on the red 
line plot; absence of the 39,800-m/z peak in the isogenic strain (E. coli DH5α/pBC-SK) 
is observed on the green line plot.(c) Box plots and spectra of the 39,800-m/z peak 
corresponding to CMY-2 detection in clinical isolates of CMY-2 producer are shown 
with red color. Spectra of non-CMY-2-producing isolates (negative controls) are shown 
with green color. (d) Comparison of spectra using ampicillin (100 µg/ml) as inductor. 
Box plots and spectra of three different CMY-2 positive E. coli grown in presence and 
in absence of ampicillin (AMP). A specific color (blue, magenta and green) represents 
the same clinical isolate in both conditions. x and y axes show m/z values and intensity 




















Figure 2. Comparison of peak profiles (m/z) generated by MALDI-TOF MS in the 
molecular mass spectra from 35,000 to 45,000 Da. Mass peaks corresponding to CMY-
2 β-lactamases (~39,800 Da) are indicated with arrows with solid lines. This peak was 
detected in representative clinical isolates of CMY-2-producing E. coli (a), K. 
pneumoniae (c), P. mirabilis (e) and S. enterica (g), and was consistently absent in non-


















Table 1. Characterization of CMY-2-producing isolates by MALDI-TOF MS analysis  







E. coli VCMY-3 Pet/Dog blaCMY-2 + 
E. coli VCMY-25 Pet/Dog blaCMY-2 + 
E. coli VCMY-27 Pet/Dog blaCMY-2 + 
E. coli VCMY-35 Pet/Cat blaCMY-2 + 
E. coli VCMY-51 Pet/Dog blaCMY-2 + 
E. coli VCMY-89 Pet/Cat blaCMY-2 + 
E. coli VCMY-103 Pet/Cat blaCMY-2 + 
E. coli VCMY-104 Pet/Cat blaCMY-2 + 
E. coli VCMY-105 Pet/Cat blaCMY-2 + 
E. coli VCMY-106 Pet/Cat blaCMY-2 + 
E. coli VCMY-107 Pet/Cat blaCMY-2 + 
E. coli VCMY-108 Pet/Cat blaCMY-2 + 
E. coli VCMY-110 Pet/Cat blaCMY-2 + 















































































































E. coli VTEM-37 Pet/Dog blaTEM-1 - 
E. coli VTEM-38 Pet/Dog blaTEM-1 - 
E. coli VTEM-82 Pet/Dog blaTEM-1 - 
E. coli VTEM-86 Pet/Dog blaTEM-1 - 
E. coli VTEM-93 Pet/Dog blaTEM-1 - 












E. coli VS6 Pet/Dog ND - 
E. coli VS15 Pet/Dog ND - 












E. coli HBC1a1 (TC) Laboratory Strain rpsL/ blaCMY-2 + 
E. coli HB101 Laboratory Strain rpsL - 
E coli DH5α Laboratory Strain gyrA96 - 
E. coli DH5α + pB -SK Laboratory Strain catA1 - 
E. coliDH5α + pBC-SK- CMY-2(pBL-II-
CMY-2) 
Laboratory Strain catA1/blaCMY-2 + 
E. coli ATCC 25922 Laboratory Strain ND - 
E. coli ATCC35218 Laboratory Strain blaTEM-1 - 
    





























    












    
























    








































AAKTEQQIADIVNRTITP 1969.23 1969,07 21-38 
AAKTEQQIADIV 1286.45 1286,69 21-32 
CMY-2 amino acid sequence from E. coli (GenBank accession no. AB212086) was used as a 




















 The CMY-2 β-lactamase was directly detected by MALDI-TOF MS. 
 A new, fast and low-cost protocol with a less time-consuming manner was 
developed. 
 A distinctive peak around 39,800 Da was found in all CMY-2 producing 
strains. 
 A perfect test and a high discriminative power were observed. 
 Direct CMY-2 detection on positive blood cultures bottles was achieved. 
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